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Abstract 19 
Daily physical activity is reduced in precapillary pulmonary hypertension (PH) but the 20 
underlying mechanisms are inadequately explored. We sought to investigate clinical and 21 
physiological relations of daily physical activity and profile differences between less and 22 
more active patients with precapillary PH. A prospective, cross-sectional study of 20 23 
patients with precapillary PH who undertook a) a comprehensive clinical assessment, b) a 24 
preliminary treadmill test, c) 7-day monitoring of daily walking intensity with triaxial 25 
accelerometry and d) a personalized treadmill test corresponding to the individual patient 26 
mean daily walking intensity with real-time physiological measurements. Significant 27 
clinical correlations with individual patient mean walking intensity (1.71±0.27 m/s2) were 28 
observed for log N-terminal pro-brain natriuretic peptide (log-NTproBNP: r=-.75, 29 
p=<.001), age (r=-.70, p=.001), transfer factor for carbon monoxide %predicted (r=.51, 30 
p=0.022) and 6-minute walk distance (r=.50, p=.026). Significant physiological 31 
correlations were obtained for heart rate reserve (r=.68, p=.001), quadriceps tissue 32 
oxygenation index (Q-StO2: r=.58, p=.008), change in Q-StO2 from rest (r=.60, p=.006) 33 
and ventilatory equivalent for oxygen uptake (r=-.56, p=.013). Stepwise multiple 34 
regression analyses retained log-NTproBNP (R2=0.55), heart rate reserve (R2=0.44) and 35 
Q-StO2 (R2=0.13) accounting for a significant variance in individual walking intensity. 36 
Less active patients had greater physical activity-induced cardiopulmonary impairment, 37 
worse quadriceps oxygenation profile and compromised health-related quality of life 38 
compared to more active patients. These preliminary findings suggest a significant 39 
relation between right ventricular and peripheral muscle oxygenation status and reduced 40 
daily physical activity in precapillary PH. Further research is warranted to unravel the 41 
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physiological determinants, establish clinical predictors, and identify beneficial 42 
interventions. 43 
New & Noteworthy 44 
Daily physical activity holds promise to be a meaningful, patient-related outcome 45 
measure in pulmonary hypertension. In this study, novel findings in a representative 46 
sample of patients with precapillary pulmonary hypertension link reduced daily walking 47 
activity, as measured by triaxial accelerometry, with compromised right ventricular and 48 
pulmonary vascular status, peripheral muscle oxygenation and health-related quality of 49 
life. This provides a preliminary insight into the physiological mechanisms and clinical 50 
predictors of daily physical activity in precapillary pulmonary hypertension.  51 
Keywords: pulmonary arterial hypertension, daily physical activity, right ventricle, 52 
skeletal muscle oxygenation.53 
 4
Introduction 54 
Precapillary pulmonary hypertension (PH) comprises primarily pulmonary arterial 55 
hypertension (PAH; group 1) and chronic thromboembolic pulmonary hypertension 56 
(CTEPH; group 4) and is characterised by progressive elevation of vascular resistance in 57 
the precapillary pulmonary vasculature and right heart failure (13).  Despite important 58 
advances in the understanding and targeted therapy to date, the morbidity and mortality in 59 
precapillary PH remain high. Typically, patients suffer progressive dyspnoea, impaired 60 
exercise capacity and health-related quality of life (HRQoL), and premature death (1, 13, 61 
37).  62 
Physical activity is defined as the bodily movement produced by the contraction of 63 
skeletal muscle that increases energy expenditure above the basal level and can be 64 
described by dimensions of intensity, frequency, duration, mode and context (14). Daily 65 
physical activity is an important dimension of HRQoL in cardiopulmonary disease (10, 66 
43) and satisfies the core requirement of a meaningful patient-centered endpoint in 67 
clinical trials, defined to be a direct measure of how a patient “feels, functions or 68 
survives” where “function” refers to the ability to carry out normal daily activities (15). 69 
Regular engagement in physical activity is recommended in PH (13). However, research 70 
shows significantly reduced daily physical activity in patients with precapillary PH 71 
compared to healthy controls and poorer survival in more sedentary patients (21, 36, 39, 72 
45).  73 
The causes of reduced daily physical activity in PH are not adequately explored.  Our 74 
perception of the underlying mechanisms remains intuitively focused on pulmonary 75 
vasculopathy and right ventricular dysfunction and limited to extrapolations from 76 
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standardized exercise testing (40), which may not correspond well to daily physical 77 
activity (28, 47). Notably, the role of peripheral muscles has not been investigated. This is 78 
despite growing evidence of skeletal muscle abnormalities in PAH (31) and recent 79 
findings suggesting that estimates of skeletal muscle oxygenation may reflect the 80 
pathophysiology of PAH (32, 33). The ability of the usual clinical variables collected in 81 
precapillary PH to predict daily physical activity is not well established. 82 
The purpose of this study was therefore to explore the physiological mechanisms and 83 
predictors of reduced physical activity in precapillary PH. To this aim, we investigated 84 
relations of patient daily walking intensity as measured by accelerometry with a) routine 85 
clinical measures and b) cardiopulmonary and peripheral muscle physiological responses 86 
during laboratory exercise corresponding to individual daily walking intensities. We also 87 
explored differences between lesser and more active patients. We hypothesized that along 88 
with pulmonary vasculature and right ventricular status, peripheral muscle function might 89 
be a pertinent factor in reducing daily physical activity in precapillary PH. 90 
Materials & Methods 91 
Study Sample  92 
Consecutive patients with stable PAH and technically inoperable (distal) CTEPH who 93 
attended the Scottish Pulmonary Vascular Unit between November 2014 and October 94 
2015 were eligible. The diagnosis had been previously established by right heart 95 
catheterisation as recommended (13). Clinical stability was defined as a) no 96 
hospitalization for precapillary PH and b) no escalation in therapy for PH or diuretics 97 
within 3 months. Exclusion criteria were pulmonary endarterectomy or comorbidities 98 
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interfering with physical activity and treadmill testing. Approval from the West of 99 
Scotland Research Ethics Committee (14/WS/1075) and written consent were obtained. 100 
Initial evaluation 101 
Data were collected on WHO functional class, maximum voluntary ventilation 102 
(MVV=FEV1 x 35) (1) and transfer factor for carbon monoxide (TLCO) corrected for 103 
haemoglobin concentration (19). They also completed the patient-reported Cambridge 104 
Pulmonary Hypertension Outcome Review (CAMPHOR) (25), a well-validated 105 
questionnaire for the assessment of HRQoL in PH. CAMPHOR is probably the most 106 
widely studied questionnaire in PH and has been shown to predict clinical deterioration in 107 
idiopathic PAH and CTEPH (24). However, CAMPHOR questionnaire has not been 108 
validated against objective, accelerometry measures of daily physical activity to date. 109 
Finally, N-terminal pro-brain natriuretic peptide (NTproBNP) and 6-minute walk 110 
distance (6MWD) were retrieved from the medical record (median interval: 30 days for 111 
both). 112 
Preliminary treadmill test 113 
All subjects performed an incremental treadmill test (RAM 770M Treadmil; RAM 114 
Medical and Industrial Instruments & Supplies, Padova, Italy operated through the CASE 115 
ES Ergospirometry Testing System; GE Healthcare, Freiburg, Germany) at an initial 116 
speed of 1.4 km/h that increased by 0.8 km/h every 3 minutes to the limit of tolerance. 117 
During the test, minute-by-minute walking intensity was measured in units of 118 
acceleration (m/s2) using a triaxial activity monitor (DynaPort MoveMonitor; McRoberts, 119 
Netherlands). In this manner, a range of individualised walking intensities were plotted 120 
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against treadmill speeds and a predicted equation for walking intensity and corresponding 121 
treadmill speed was generated for each patient.  122 
Accelerometry 123 
Subjects were fitted with DynaPort accelerometers attached to an elastic strap and 124 
positioned over the L2 vertebra (an approximation of the body’s center of mass) to record 125 
their daily walking intensity continuously for 7 days, excluding sleep and water-based 126 
activities. Measurements were considered sufficient if a technically acceptable signal was 127 
obtained daily for a minimum of 12 consecutive hours, during 5 consecutive days (18, 128 
34). The DynaPort is a validated accelerometer that provides reliable measures of 129 
physical activity including postures, steps and movement intensities during locomotion, 130 
and even under sedentary conditions (5, 37, 46). The intensity with which a person carries 131 
out activities of daily living is a unique measure of daily life activity, which is a 132 
fundamental part of recommendations for health maintenance (14) and an important 133 
aspect of the overall physical activity in chronic lung disease (34). Importantly, walking 134 
intensity can be easily and accurately reproduced on the treadmill, thus allowing the 135 
study of individual physiological responses during activity in the laboratory setting [17, 136 
18]. 137 
Personalized treadmill test 138 
Within 2 weeks, patients underwent a final, three-stage treadmill protocol during 139 
which they sequentially: 1) stood still on treadmill, 2) warmed up at a speed of 1.4 km/h, 140 
and 3) walked at a predetermined treadmill speed corresponding to their individual daily 141 
walking intensity (calculated by using the predicted equation for walking intensity and 142 
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treadmill speed generated during the preliminary treadmill test. The duration of each 143 
stage was 4 minutes in order to reach a steady physiological state. 144 
Continuous physiological measurements were obtained throughout as described 145 
below. The resting and exercise value for all the physiological variables considered for 146 
the analysis was the average value of all the acquired data during the last minute of the 147 
first and third stage of the personalized treadmill protocol, respectively.  148 
Metabolic profile 149 
Oxygen uptake (VO2), minute ventilation (VE) and ventilatory equivalent ratios for 150 
oxygen uptake (VE/VO2) and carbon dioxide (VE/VCO2) were recorded breath-by-breath 151 
(CASE ES, GE Healthcare, Freiburg, Germany). Oxyhaemoglobin saturation (SpO2) was 152 
recorded continuously by pulse oximetry (OxywatchTM MD300C63, Beijing Choice 153 
Electronic Tech. Co. Ltd, China). Electrocardiography was used to calculate heart rate 154 
(HR) reserve (HRR), defined as the difference between age-predicted maximal HR (220-155 
age) and peak HR (1). 156 
Central hemodynamics 157 
Estimates of stroke volume and cardiac output were measured using impedance 158 
cardiography technology (PhysioFlow®, Manatec Biomedical, France). PhysioFlow uses 159 
variations in the transthoracic impedance to a high-frequency (75 kHz), low-amperage 160 
(1.8 mA) alternating current across the thorax during cardiac ejection to calculate stroke 161 
volume (4) and it has been previously validated (42) and used in PAH (12). Application 162 
of six transthoracic electrodes, autocalibration, verification of signal quality and artifact 163 
detection were performed as instructed by the manufacturer (4). The PhysioFlow 164 
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principle is based on the assumption that variations in impedance to a high-frequency 165 
(75kHz), low-magnitude (1.8 mA) alternating current across the thorax during cardiac 166 
ejection result in a waveform from which stroke volume (SV) can be calculated. Initially, 167 
a SV index (SVI) is calculated at rest by evaluating 30 consecutive heart beats 168 
(autocalibration procedure) using the largest impedance difference during systole, the 169 
largest rate of change in the impedance signal (contractility index), the thoracic fluid 170 
inversion time, heart rate, and the pulse pressure (systolic minus diastolic arterial 171 
pressure). Cardiac output is then calculated by multiplying the SVI by body surface area 172 
and HR [R-R interval determined on the electrocardiographic (ECG) first derivative]. The 173 
system was auto-calibrated before exercise tests on the treadmill. Signal quality was 174 
verified by visualizing the ECG tracing and its first derivative (dECG/dt) and the 175 
impedance waveform (ΔZ) with its first derivative (dZ/dt). If unstable signal recording 176 
occurred, the system did not allow the test to proceed, and a new calibration was 177 
performed. After shaving and cleaning the skin, two pairs of electrodes were firmly 178 
positioned at the left base of the neck and on the back at the xiphoid level for transmitting 179 
and receiving electrical currents. Two electrodes were also placed on the chest (V1/V6 180 
position) for the ECG signal. The auto calibration procedure was started after a period of 181 
at least 5 minutes during which patients were sitting immobile on a chair. Cardiac output 182 
values were stored beat-by-beat. 183 
Quadriceps oxygenation 184 
Quadriceps tissue oxygenation index (Q-StO2), as an expression of the local 185 
microvascular oxygenation status, was measured using spatially resolved near infrared 186 
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spectroscopy (NIRO-200NX®, Hamamatsu Photonics KK, Japan). Tissue oxygenation 187 
index is essentially the ratio of oxygenated to total tissue hemoglobin concentration 188 
expressed as [oxyhaemoglobin/(oxyhaemoglobin + deoxyhaemoglobin)] × 100 (%) and 189 
represents an index of the dynamic balance between local tissue oxygen delivery and 190 
utilisation in health and disease (3, 23). We have previously shown strong correlations 191 
between quadriceps tissue oxygenation index (Q-StO2) and mixed venous oxygen 192 
saturation measured in the pulmonary artery in PAH subjects, both at rest and exercise 193 
(32, 33). 194 
To measure Q-StO2, one transcutaneous probe (S-type) housed in a black rubber 195 
holder and fixed using a double-sided adhesive tape, was placed on the belly of each 196 
vastus lateralis muscle, 10-12 cm above the lateral epicondyle. Briefly, one fiber optic 197 
bundle carries the near-infrared light produced by the laser diodes to the tissue of interest, 198 
and a second fiber optic bundle returns the transmitted light from the tissue to a 199 
photodetector in the spectrometer. The intensity of incident and transmitted light was 200 
recorded continuously and, along with the relevant specific extinction coefficients, was 201 
used to measure changes in the oxygenation status of hemoglobin + myoglobin (Hb+Mb) 202 
and then covered with a black rubber holder and fixed using a double-sided adhesive 203 
tape, thus minimizing the intrusion of extraneous light and loss of near-infrared light. The 204 
values shown for Q-StO2 are the average from both legs. 205 
 Estimated systemic oxygen delivery was calculated as the product of cardiac output 206 
and arterial oxygen content. The latter was calculated as the product of 1.34 × 207 
hemoglobin concentration × %SpO2. The systemic arteriovenous oxygen content 208 
difference (a-vO2 difference) was calculated by dividing oxygen uptake by cardiac output 209 
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(Fick principle) whereas the systemic oxygen extraction ratio was calculated as the ratio 210 
of the a-vO2 difference to arterial oxygen content (18). 211 
Statistical analysis 212 
Data are reported as means ± SD or median with 95% confidence interval of median. 213 
NTproBNP was log-transformed due to positive skewing. Associations of mean daily 214 
walking intensity were examined using the Pearson’s correlation coefficient. Significant 215 
parameters were further tested using stepwise multiple regression analysis. Patients were 216 
dichotomised using the median daily walking intensity for an unpaired group comparison 217 
using the Mann-Whitney U-test. Data were analyzed using the SPSS statistical package 218 
(v 20, SPSS Inc., Chicago, IL). The level of significance was set at p<.05. 219 
The critical sample size of the study was calculated using Q-StO2 as the primary 220 
variable, based on a previous study which investigated the association between daily 221 
walking intensity (also measured by the same activity monitor) and quadriceps muscle 222 
oxygenation in 18 COPD patients (18). On the basis of an expected effect size of 0.589 223 
that had been calculated from the mean difference (14.95%) and the corresponding 224 
standard deviation (25.38%) of Q-StO2 (18), the calculated critical sample size to address 225 
the objectives of the present study using multiple regression analysis with power of 0.80 226 
and 2-sided alpha significance level of 0.05 (calculated using GPower statistical software, 227 
v 3.1; Heinrich Heine University Düsseldorf, Germany) was 18 patients. 228 
Results 229 
Patient characteristics 230 
Patients characteristics are presented in Table 1. Twenty patients were enrolled, 231 
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completed the protocol without adverse effects and were included in the analysis (Figure 232 
1). Stroke volume profile of 3 (15%) patients had to be excluded due to invalid 233 
impedance cardiography signal. Sixteen patients had PAH (9, idiopathic PAH; 6, 234 
connective tissue disease associated-PAH; 1, PAH after correction of congenital heart 235 
disease) and 4 patients had CTEPH. None of the patients had previously had a significant 236 
cardiac shunt detected at transthoracic echocardiogram, cardiac magnetic resonance 237 
imaging or right heart catheterisation. All patients were on PH-specific therapy: 10, 238 
monotherapy (7, phosphodiesterase-5 inhibitor (PDEi); 2, stimulator of soluble guanylate 239 
cyclase (sGC); 1, endothelin receptor antagonist (ERA)) and 10, combination therapy (6, 240 
PDE-i+ERA; 1, ERA+sGC; 3, PDEi+ERA+inhaled prostanoid). None of the patients was 241 
on heart rate-limiting medication. 242 
In the preliminary test, the tolerated treadmill speeds ranged between 0.8 and 6.2 km/h 243 
corresponding to walking intensities ranged between 1.07 to 3.96 m/s2. In the 244 
personalized test, the treadmill speeds ranged from 0.8 to 3.3 km/h corresponding to daily 245 
walking intensities between 1.08 and 2.22 m/ss. 246 
Total and daily time of accelerometry monitoring were 6.4±0.94 days and 864±94 247 
min, respectively. Mean and median daily walking intensity were 1.71±0.27 m/s2 and 248 
1.78 (1.55, 1.83) m/s2, respectively. Daily walking time was 61±26 min and daily steps 249 
were 4897±2209 indicating a generally sedentary lifestyle [43]. 250 
Correlations and predictors of daily walking intensity 251 
Significant clinical correlations with mean daily walking intensity were observed for 252 
log-NTproBNP (r=-.75, p=<.001), age (r=-.70, p=.001) (Figure 2) and 6MWD (r=.50, 253 
p=.026). Significant physiological correlations with mean daily walking intensity were 254 
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observed for HRR (r=.68, p=.001), Q-StO2, (r=.58, p=.008), change in Q-StO2 from rest 255 
to mean daily walking intensity (r=.60, p=.006), VE/VO2 (r=-.56, p=.013) and TLCO 256 
%predicted (r=.51, p=0.022) (Figure 2). There was no significant association between 257 
estimates of stroke volume at rest or exercise and mean daily walking intensity.  258 
Stepwise multivariate regression analysis of significant clinical measures retained log-259 
NTproBNP and age accounting for 75% of the variance in mean daily walking intensity, 260 
(Table 3). Repeated for the significant physiological measures, analysis retained HRR 261 
and Q-StO2 at activity accounting for 57% of the variance in mean daily walking intensity 262 
(Table 3). 263 
Comparison between less and more active patients 264 
There was no significant difference in VO2 between less and more active patients. 265 
Less active patients had significantly increased age, log-NTproBNP, VE/MVV, VE/VO2, 266 
CAMPHOR score and decreased TLCO %predicted, HRR, Q-StO2 at mean daily walking 267 
intensity and Q-ΔStO2.  They also showed a 100-metre reduction in 6MWD compared to 268 
more active patients (Table 1 and 2).  269 
Discussion 270 
This exploratory study in a representative cohort with precapillary PH reports on 271 
significant associations of indices of right ventricular (log-NTproBNP, HRR) and 272 
pulmonary vascular (TLCO %predicted) status with mean daily walking intensity. In 273 
exercise conditions reproducing individual daily physical activity levels, measures of 274 
quadriceps oxygenation (Q-StO2 at activity, ΔQ-StO2) and ventilatory efficiency 275 
(VE/VO2) were also associated significantly with mean daily walking intensity. Log-276 
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NTproBNP, HRR and Q-StO2 at mean activity levels predicted a significant proportion of 277 
the variance in mean daily walking intensity. Finally, the profile of less active patients 278 
comprised greater cardiorespiratory impairment, worse quadriceps oxygenation profile 279 
and compromised HRQoL compared to more active patients.   280 
Overall, the present population adopted either a sedentary lifestyle, defined as daily 281 
steps of <5000 (43) (12 out of 20 patients; 60%) or a low-active lifestyle, defined as daily 282 
steps between 5000 and 7500 (43) (8 out of 20 patients; 40%). Also, mean daily walking 283 
intensity in the present cohort (1.71 m/s2) compares with that adopted by older patients 284 
with moderate/severe COPD (spirometric classes II/III), typically corresponding to 1.8 285 
m/s2 (18, 34). This adds to previous evidence (21, 36, 39, 45) of reduced measures of 286 
daily physical activity in precapillary PH.  287 
The hemodynamic profile in precapillary PH depends mostly on right ventricular 288 
performance (16). NT-proBNP, a nonspecific marker of myocardial dysfunction, is 289 
considered an indicator of the right ventricular status and a prognostic marker at 290 
diagnosis and during follow-up in precapillary PH (13). Out of 35 variables, NT-proBNP 291 
was also the strongest predictor of peak VO2 and a significant predictor of 6MWD in 292 
patients with chronic heart failure (11). In line, we observed a strong negative correlation 293 
between log-NTproBNP and mean daily walking intensity whereas log-NTproBNP 294 
predicted more than half of the variance in mean daily walking intensity. It was 295 
significantly elevated in less active patients. 296 
Heart rate profiles in precapillary PH are though to reflect the burden of the right 297 
ventricle (16).  In the setting of right ventricular failure and fixed/reduced stroke volume 298 
response with exercise, patients with precapillary PH become dependent on a 299 
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compensatory increase in HR responses to maintain or increase cardiac output and 300 
preserve tissue oxygenation (16). Hence, the HR-VO2 relationship in precapillary PH is 301 
left-shifted with submaximal HR values trending higher than normal (1). Accordingly, 302 
chronotropic response (peak walking HR minus resting HR) and resting HR in PAH, 303 
have been independently associated with 6MWD (35) and prognosis (16), respectively. 304 
Here, we extend these findings by showing a strong relation between HRR and mean 305 
daily walking intensity and significantly reduced HRR in less active patients compared to 306 
more active patients. HRR also predicted almost half of the variance in individual mean 307 
daily walking intensity. 308 
Higher HR accounted for the higher cardiac output in less active patients in the present 309 
study. Estimates of stroke volume did not differ between less and more active patients 310 
and it was dissociated with daily walking activity. Cardiac output also did not correlate 311 
with daily walking intensity in the present cohort. Previous studies using right heart 312 
catheterisation data also failed to show correlation between cardiac output/index and 313 
daily physical activity levels in precapillary PH (21, 36). In contrast, TLCO %predicted, 314 
reflecting pulmonary capillary volume, was also negatively associated with mean daily 315 
walking intensity and 40% lower in less active patients. Collectively, our findings on NT-316 
proBNP and HRR profiles and TLCO %predicted suggest a significant relation between 317 
the right ventricular and pulmonary capillary volume status and daily physical activity in 318 
precapillary PH.  319 
The ventilatory response becomes exaggerated in precapillary PH due to 320 
chemo/ergo/baro- receptor sensitivity, dead space ventilation and hypoxemic drive. 321 
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Premature lactic acidosis at the peripheral muscles due to hypoxemia will also increase 322 
the ventilatory drive on activity. Physiologically, the ventilatory response to the 323 
metabolic requirement is reflected in the VE/VO2 relationship (1). Accordingly, we 324 
observed a negative correlation between VE/VO2 and mean daily walking intensity and 325 
VE/VO2 and VE/MVV were significantly higher among less active patients (by almost 326 
20% and 40%, respectively). VE/VCO2, ratio, which is an important index of ventilatory 327 
efficiency and prognostic significance in precapillary PH, also differed between the 2 328 
groups (58 vs. 44).  However, it did not reach statistical significance, possibly, due to 329 
submaximal testing and small sample size. Such an exaggerated ventilatory response is 330 
highly relevant to physical activity as it may promote dyspnoea and cessation of exercise.  331 
Patients with PAH exhibit significant morphological and functional changes of the 332 
quadriceps muscle including alteration in the muscle fibre type, muscle atrophy, reduced 333 
capillarity and oxidative capacity, and endothelial dysfunction (31). These abnormalities 334 
may impair the local tissue oxygen delivery and utilization capacity, muscle strength and 335 
exercise capacity (20). Muscle characteristics were unrelated to the hemodynamic 336 
severity (20) and targeted exercise training reversed abnormalities and improved exercise 337 
capacity (6, 26).  This suggests that peripheral muscle abnormalities may be implicated 338 
independently in the exercise pathophysiology of PAH. Here, Q-StO2 at activity 339 
correlated with mean daily walking intensity, predicted a clinically significant amount of 340 
the variance in daily walking intensity, and was significantly lower in less active patients. 341 
Of significance, ΔQ-StO2 responses contrasted sharply between the patient groups.  Less 342 
active patients showed a fall in Q-StO2 whereas more active patients experienced an 343 
increase in Q-StO2 at individual mean daily walking intensity. 344 
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Factors determining local muscle oxygenation are modulated by the rate of oxygen 345 
delivery and oxygen extraction (8). Whereas arterial oxygen content and systemic oxygen 346 
delivery did not differ between the present patient groups, less active patients had 347 
significantly reduced a-vO2 difference and ~ 10% reduction in oxygen extraction ratio 348 
compared to more active patients. Collectively, our novel findings on estimates of muscle 349 
oxygenation suggest a strong relationship between the capacity to enhance local muscle 350 
oxygenation and better preserved daily physical activity and they provide support to the 351 
peripheral muscle hypothesis (29). They also add to previous evidence showing: a) 352 
impaired oxygen extraction rate during maximal exercise in PAH patients compared to 353 
patients with pulmonary venous hypertension (41), b) lower muscle resting StO2 in PAH 354 
compared to CHF and healthy subjects (9), c) greater quadriceps oxygen delivery-to-355 
utilization inequalities (Δ[Mb-HHb]; change in deoxygenated myoglobin from rest to 356 
exercise) in PAH compared to healthy subjects, which accounted for a slower rate of 357 
adaptation of aerobic metabolism at exercise (2) and d) reduced quadriceps oxygenation 358 
(lower Q-ΔStO2, higher Δ[Mb-HHb]) in PAH compared to normal subjects even during 359 
submaximal exercise (22). Δ[Mb-HHb] was also related to reduced quadriceps capillarity 360 
and strength, and lower VO2 (22). 361 
Certainly, our study design does not allow for proof of causality and further research is 362 
required before a primary impairment of peripheral muscle oxygenation is considered a 363 
true limiting factor rather than a mere consequence of deconditioning or reflection of 364 
hypoxemia. Nonetheless, we found no association between Q-StO2 and SpO2 or arterial 365 
oxygen content at rest/exercise (p>0.5 for all). Furthermore, Q-ΔStO2 and Δ[Mb-HHb] in 366 
PAH subjects have been previously shown to remain unchanged with oxygen 367 
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supplementation (22).  368 
A unifying explanation may lie within the seemingly paradoxical absence of 369 
difference in VO2 between less and more active patients. It is possible that the metabolic 370 
requirements of the increased workload (reduced HRR) of the stressed heart (increased 371 
log-NTproBNP) and increased/inefficient ventilation (increased VE/MVV, VE/VO2) in 372 
less active patients had matched the oxygen requirements of increased daily walking 373 
intensity in more active patients. Teleologically, it may that both patient groups had 374 
adjusted their activity to a certain threshold of oxygen/energy cost that allowed for 375 
acceptable exertional symptoms such as muscle fatigue and breathlessness (as suggested 376 
by responses in ventilation and estimates of quadriceps oxygenation). Ultimately, less 377 
active patients showed convincingly compromised HQoL (worse CAMPHOR scores). 378 
The current study is limited by its cross-sectional design, small sample and small 379 
number of patients with advanced disease willing to undergo such a complex study 380 
protocol. Stroke volume profile of 3 (15%) patients had to be excluded due to invalid 381 
impedance cardiography signal but this limitation is inherent to impedance cardiography 382 
and this figure is similar to previously published experience in precapillary PH (12). 383 
Furthermore, the absence of direct measurement of peripheral muscle strength does not 384 
allow for further exploration of the role of the peripheral muscle. Arterial oxygen content 385 
was estimated using continuous SpO2 readings at the expense of possible reduced 386 
accuracy in the hypoxaemic patients compared to invasive arterial blood sampling. For 387 
patient comfort, measurements of 6MWD and NT-proBNP were retrospective in nature. 388 
However, in the context of clinical stability (a prerequisite for patient inclusion in the 389 
study), an interval of 30 days is a clinically acceptable collection period for both 390 
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measures. With regards to walking intensity, albeit an attractive measure of the most 391 
important mode of human physical activity, it ignores physical activities not involving 392 
walking. This may have introduced some limitations in the assessment, interpretation and 393 
prediction of the overall physical activity. Finally, this study did not investigate the 394 
possible impact of specific diseases and drug therapy on muscle function or the effect of 395 
unmeasured variables such as environmental, social and personal factors to daily physical 396 
activity. These factors might have accounted for the unexplained variance in daily 397 
walking intensity and the moderate correlation of 6MWD with daily walking intensity. Of 398 
note, CAMPHOR scores did not correlate with daily walking activity. Taken together 399 
with previously shown weak-to-moderate correlations of accelerometry data with 6MWD 400 
and patient-reported questionnaire scores (39), these findings question the surrogate value 401 
of routine clinical tools in the prediction of daily physical activity in precapillary PH. 402 
Conclusions 403 
Daily physical activity holds promise to be a meaningful, patient-related outcome 404 
measure in PH. Our preliminary findings suggest a significant relation between estimates 405 
of right ventricular status (as assessed by NT-proBNP levels and heart rate responses) 406 
pulmonary vascular status (as assessed by TLCO %predicted), peripheral muscle 407 
oxygenation and HRQoL with reduced daily walking intensity in precapillary PH. 408 
However, further research is warranted to unravel the physiological determinants and 409 
establish the clinical predictors of this phenomenon. The role of muscle function in the 410 
natural history of precapillary PH merits particular focus as it offers a potential target for 411 
effective interventions. 412 
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Figure Captions 422 
Figure 1: Study flow chart. BMI: body mass index; WHO FC: World Health 423 
Organization functional class; PFT: pulmonary function testing; 6MWD: 6-minute walk 424 
distance; log-NTproBNP: log-transformed N-terminal pro-brain natriuretic peptide. VO2: 425 
oxygen uptake; VE: minute ventilation; MI: movement intensity; VE/VO2: ventilatory 426 
equivalent ratio for oxygen; VE/VO2: ventilatory equivalent ratio for carbon dioxide; 427 
HRR: heart rate reserve; SpO2: oxyhaemoglobin saturation; SV: stroke volume; CO: 428 
cardiac output; Q-StO2: quadriceps tissue oxygenation index; Q-ΔStO2: change in Q-StO2 429 
from rest to exercise. The study protocol for each patient was concluded within 2 weeks. 430 
* Retrospective data (median interval: 30 days); § Resting and exercise value was the 431 
average value obtained during the last minute of the 1st and 3rd stage of the personalised 432 
treadmill test (see text for explanation), respectively; # SV and CO profile of 3 patients 433 
was excluded due to invalid impedance cardiography signal. 434 
 435 
Figure 2: Correlations (Pearson’s r) between daily walking intensity recorded by 436 
triaxial accelerometer and log N-terminal pro-brain natriuretic peptide (log-NTproBNP) 437 
(A); age (B); heart rate reserve (HRR) (C); ventilatory equivalent ratio for oxygen uptake 438 
(VE/VO2) (D); quadriceps tissue oxygenation index (Q-StO2) at activity (E); and change 439 
in Q-StO2 from rest to activity (Q-ΔStO2) (F) in 20 patients with precapillary pulmonary 440 
hypertension. 441 
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Table 1: Clinical characteristics and comparison between less and more active patients1 442 
  Daily walking intensity, m/s2 P-value 
 
Variable All (n=20) < 1.78 (n=10) ≥ 1.78 (n=10)  
Walking Intensity, m/s2 1.71 ± 0.27 1.54 (1.29-1.75) 1.86 (1.79-2.03) <.001* 
Treadmill speed, km/hr 2.27 ± .84 1.90 (1.00-2.90) 2.95 (1.80-3.20) .037* 
Sex, m/f 8/12 4/6 4/6 N/A 
Age, yrs 54.1 ± 15.9 66.0 (44.0-73.0) 48.5 (24.0-56.0) .045* 
BMI, kg/m2 29.9 ± 5.7 28.1 (18.8-31.6) 25.5 (21.3-29.7) .705 
Idiopathic PAH 9 4 5 N/A 
CTD-PAH 6 4 2 N/A 
CHD-PAH 1 0 1 N/A 
CTEPH 4 2 2 N/A 
WHO FC, I/II/III 4/12/4 1/5/4 3/7/0 N/A 
mean PAP, mm Hg 45.1± 13.3 46.0 (32.0-57.0) 40.0 (28.0-65.0) .713 
CO, L/min 3.8 ± 1.0 3.6 (2.6-4.3) 4.3 (3.3-5.0) .102 
PVR, Wood units 11.1 ± 5.7 12.3 (6.0-13.5) 8.7 (4.8-15.2) .369 
                                                      
Values are expressed as means ± SD or median and 95% confidence interval of median. 
BMI: body mass index; PAH: pulmonary arterial hypertension; CTD-PAH: connective 
tissue disease associated PAH; CHD-PAH: PAH after correction of congenital heart 
disease; WHO FC: World Health Organization functional class; PAP, CO and PVR: 
historical pulmonary arterial pressure, cardiac output and pulmonary vascular resistance, 
respectively, measured at diagnostic right heart catheterization, prior to the initiation of 
PH-specific therapy; 6MWD: 6-minute walk distance; log-NTproBNP: log-transformed 
N-terminal pro-brain natriuretic peptide; FEV1: force expiratory volume in one second; 
FVC, forced vital capacity; TLCO: transfer factor for carbon monoxide. *Significant 
statistical difference between patient group. 
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6MWD, m 418 ± 106 361 (298-513) 469 (347-570) .076 
CAMPHOR 23.2 ± 16.8 36.5 (8.0-46.0) 11.5 (0-36.0) .041* 
log-NTproBNP, pg/mL 2.53 ± 0.53 2.99 (2.75-3.29) 2.10 (1.79-2.42) <.001* 
FEV1, %pred. 89.9 ± 19.1 93.0 (80.0-115.5) 91.0 (65.8-98.5) 0.26 
FVC, %pred. 112.4 ± 23.2 115.5 (100.3-141.5) 108.0 (90.0-122.3) 0.34 
FEV1/FVC 66.5 ± 8.5 69.0 (60.3-72.0) 66.5 (63.3-71.0) 0.62 
TLCO, % 51.1 ± 19.2 62.5 (47.9-73.0) 38.0 (29.7-53.6) 0.025 
 443 
 24
Table 2: Physiological characteristics and comparison between less and more active patients1. 444 
  Daily walking intensity, m/s2 P-value 
Variable All (n=20) < 1.78 (n=10) ≥ 1.78 (n=10)  
SpO2 activity, % 89.9 ± 7.1 86.0 (81.0-95.0) 95.0 (88.0-96.0) .1 
HRR, beats/min 61.8 ± 26.2 51.0 (9.0-57.0) 78.5 (67.0-91.0) <.001* 
SV rest/activity, ml/beat 66.5± 21.5/ 
80.9 ± 21.6 
59.2 (25.0-116.9)/ 
74.1 (42.9-137.0) 
63.6 (58.3-79.2)/ 
78.9 (72.0-91.2) 
.664/ 
.745 
CO rest/activity, l/min 5.4 ± 1.2 
8.9 ± 2.6 
5.2 (3.3-7.1) 
10.0 (6.8-16.1) 
4.8 (4.2-6.7) 
7.5 (6.8-9.3) 
.495/ 
.045* 
Q-StO2 rest/activity, % 64.1 ± 7.4/ 
65.4 ± 10.6 
63.7 (54.6-68.6)/ 
60.5 (43.4-74.5) 
65.7 (57.9-74.4)/ 
71.4 (62.0-76.4) 
.496/ 
.028* 
Q-ΔStO2, % 1.3 ± 6.6 -2.3 (-6.0-1.8) 5.1 (3.2-7.8) .003* 
VE/MVV, l/min 40.9 ± 14.3 48.9 (32.2-60.0) 30.5 (25.9-39.6) .007* 
VE/VO2 51.1 ± 18.8 55.8 (39.8-81.1) 40.6 (34.3-58.2) .041* 
VO2, ml·kg-1·min-1 9.5 ± 1.4 9.4 (7.5-11.0) 9.7 (7.9-10.5) .806 
VE/VCO2 52.1 ± 13.6 57.7 (38.4-77.0) 44.0 (40.0-56.7) .142 
Arterial oxygen content, 
ml/dl 
18.1 ± 1.42 17.3 (16.3-19.1) 19.1 (17.7-19.3) .1 
Systemic oxygen 
delivery, l/min 
1.4 ± .5 1.6 (1.1-2.6) 1.4 (1.2-1.6) .556 
                                                      
1 Values are expressed as means ± SD or median and 95% confidence interval of median. 
SpO2: oxyhaemoglobin saturation; HRR: heart rate reserve; SV: stroke volume; CO: 
cardiac output; Q-StO2: quadriceps tissue oxygenation index; Q-ΔStO2: change in Q-StO2 
from rest to exercise; VE: minute ventilation; MVV: maximum voluntary ventilation; 
VE/VO2: ventilatory equivalent ratio for oxygen; VE/VO2: ventilatory equivalent ratio 
for carbon dioxide; VO2: oxygen uptake; a-vO2 difference: arterio-venous oxygen content 
difference. *Significant statistical difference between patient groups. 
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Systemic a-vO2 
difference, mlO2/100 ml 
7.7 ± 1.6 5.9 (5.1-8.3)  8.6 (6.7-9.8) .017* 
Systemic oxygen 
extraction, % 
42 ± 11 35 (28-51) 44 (34-52) .239 
 445 
 446 
 447 
 448 
 449 
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Table 3: Independent predictors of walking intensity in the two multivariate linear regression 450 
analyses1. 451 
 452 
Unstandardised 
Regression 
coefficient 
95% CI for 
  
Standardised  
Regression 
coefficient 
Change               
statistics 
Model 1  B     SE B                 B P value R2 R2 change F change 
Constant 2.901 .171 2.540 to 3.263           -  
log-NTproBNP -.292 .068 -.436 to -.148 -.557 0.001 .555 - 22.45 
Age -.008 .002 -.013 to -.004 -.485 0.002 .755 .20 13.88 
Model 2 B SE B B P value R2 R2 change F change 
Constant .679 .286 .070 to 1.288 -  
HRR .006 .002 .001 to 0.11 .506 .015 .436 - 12.38 
Q-StO2 .010 .005 .000 to .020 .395 .049 .538 .132 9.87 
 453 
 454 
 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
 466 
 467 
 468 
 469 
 470 
 471 
 472 
 473 
                                                      
1 Model 1 contains clinical characteristics. Model 2 contains physiological characteristics. 
Log-NTproBNP: log-transformed N-terminal pro-brain natriuretic peptide; HRR: heart 
rate reserve; Q-StO2: quadriceps tissue oxygenation index. 
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